(Q39120399)

English

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

scientific article published on 28 September 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Joseph Gligorov

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Dinesh Doval

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

José Bines

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Emilio Alba

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Paulo Cortes

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Jean-Yves Pierga

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Vineet Gupta

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rômulo Costa

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Stefanie Srock

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sabine de Ducla

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ulrich Freudensprung

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Giorgio Mustacchi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

28 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1351-1360

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273343%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

1st International consensus guidelines for advanced breast cancer (ABC 1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy: Maintenance therapy in breast cancer--many questions remain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A mathematical model of drug resistance: Heterogeneous tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer intratumor genetic heterogeneity: causes and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970444-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39120399&oldid=1672291630"